Back to Search
Start Over
The prostacyclin analogue cicaprost inhibits metastasis of tumours of R 3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma.
- Source :
-
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 1992; Vol. 118 (7), pp. 497-501. - Publication Year :
- 1992
-
Abstract
- Investigations on mechanisms of metastatic tumour spread revealed a role for compounds that inhibit tumour dissemination at the time of hematogenous dissemination. The platelet aggregation inhibitor prostacyclin and its stable analogues were shown to inhibit tumour-cell-induced platelet interaction as well as tumour cell adhesive mechanisms. This study concentrates on the effect of the stable prostacyclin analogue cicaprost: 5-[(E)-(1S,5S,6S,7R)-7-hydroxy-6-[(3S,4S)-3-hydroxy-4-methylnona-1 ,6- diinyl]-bicyclo[3,3,0]octan-3-ylidene]-3-oxapentanoic acid (Schering AG), as cyclodextrin clathrate, on spontaneous tumour metastases of two different carcinomas of the rat. In Cop rats bearing spontaneously metastasizing R 3327 MAT Lu prostate carcinomas, cicaprost (1.0 mg/kg p.o. daily) inhibited the number of lung metastases by about 80%, whereas the lower doses (0.1 and 0.5 mg/kg) exhibited borderline efficacy. In female Wistar-Furth rats bearing s.c. implanted SMT 2A mammary carcinomas, spontaneously metastasizing into regional lymph nodes and lungs, cicaprost (0.1, 0.5 and 1 mg/kg) p.o. daily exhibited a dose-dependent inhibition of the number of lung metastases. Five out of ten animals treated by 1 mg/kg were free of visible lung metastases. The weight of the axillary lymph node was significantly reduced by the 1 mg/kg dose of cicaprost, whereas lower doses had no effect on the weight of the lymph nodes. The growth of the primary tumour was not influenced by cicaprost in the R 3327 MAT Lu prostate carcinoma nor in the SMT 2A mammary carcinoma in the dose range tested. In conclusion, the stable prostacyclin analogue cicaprost exhibits a strong antimetastatic action in two metastasizing tumours of the rat and interferes with the steps not only of haematogenous, but also of lymphogenous metastasis.
- Subjects :
- Animals
Antineoplastic Agents administration & dosage
Dose-Response Relationship, Drug
Epoprostenol administration & dosage
Epoprostenol pharmacology
Female
Male
Mammary Neoplasms, Experimental pathology
Neoplasm Transplantation
Prostatic Neoplasms pathology
Rats
Rats, Inbred F344
Rats, Inbred WF
Tumor Cells, Cultured
Antineoplastic Agents pharmacology
Epoprostenol analogs & derivatives
Neoplasm Metastasis prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 0171-5216
- Volume :
- 118
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Journal of cancer research and clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 1624541
- Full Text :
- https://doi.org/10.1007/BF01225263